Media
The Mentor with Mark Bouris (video)
Developing Cancer Cures through the ASX \ Going Public with Leslie Chong & Paul Hopper
Proactive Investors
Imugene doses first patient for VAXINIA bile tract cancer trial in Melbourne
Proactive Investors
Imugene doses first patient in IV arm of Phase 1 onCARlytics trial targeting solid cancers
Proactive Investors
Imugene and Kincell Bio form manufacturing and process development partnership
Proactive Investors
Imugene expands bile tract cancer study as patient shows complete response during MAST trial phase
Proactive Investors
Imugene shines at AACR with promising cancer therapy results from VAXINIA and HER-Vaxx
Proactive Investors
Imugene granted China patent for Oncolytic Virotherapy CF33
Proactive Investors
Imugene has VAXINIA technology selected for presentation at Cholangiocarcinoma Foundation conference
Proactive Investors
Imugene with Proactive at ASX Small and Mid Cap Conference
Proactive Investors
Imugene progresses onCARlytics solid tumour trial to combination arm
SmallCaps
Imugene’s onCARlytics clears Phase 1 milestone in solid tumour therapy trial
Gen Bio